JEH Stock Overview
A biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
genOway Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.54 |
| 52 Week High | €4.68 |
| 52 Week Low | €3.10 |
| Beta | 0.55 |
| 11 Month Change | 3.21% |
| 3 Month Change | -10.61% |
| 1 Year Change | -13.24% |
| 33 Year Change | -24.36% |
| 5 Year Change | 218.92% |
| Change since IPO | -40.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| JEH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -0.2% | 0.8% |
| 1Y | -13.2% | -16.9% | 9.1% |
Return vs Industry: JEH exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: JEH underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| JEH volatility | |
|---|---|
| JEH Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: JEH has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: JEH's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 128 | Alexandre Fraichard | www.genoway.com |
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines.
genOway Société anonyme Fundamentals Summary
| JEH fundamental statistics | |
|---|---|
| Market cap | €34.06m |
| Earnings (TTM) | €1.26m |
| Revenue (TTM) | €28.08m |
27.1x
P/E Ratio1.2x
P/S RatioIs JEH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JEH income statement (TTM) | |
|---|---|
| Revenue | €28.08m |
| Cost of Revenue | €12.36m |
| Gross Profit | €15.72m |
| Other Expenses | €14.47m |
| Earnings | €1.26m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 55.99% |
| Net Profit Margin | 4.47% |
| Debt/Equity Ratio | 35.9% |
How did JEH perform over the long term?
See historical performance and comparison